NASDAQ$CELC
Celcuity Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Celcuity's Q2 2022 financial results were announced, and a corporate update was provided.
Celcuity reported a net loss of $10.0 million for the second quarter of 2022, compared to a net loss of $14.0 million for the second quarter of 2021. The company's operating expenses were $9.6 million, and R&D expenses were $8.4 million. Celcuity had cash and cash equivalents of $66.9 million as of June 30, 2022.
- Breakthrough Therapy Designation was granted to gedatolisib by the FDA.
- Early phase study of gedatolisib in combination with palbociclib and fulvestrant showed promising efficacy and tolerability.
- Phase 3 clinical trial, VIKTORIA-1, remains on track to dose the first patient in the next few months.
- A $100 million private placement and an amendment to increase the debt financing facility to $75 million are expected to fund operations through 2025.
Headline financials
Revenue & EPS history
Celcuity · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-0.9%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+1.8%
Avg return
30 days after
38%
13 / 34 earnings
Positive
+23.3%
Q4 2023
Best reaction
-13.5%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +5.5% | -4.7% | -32.5% | |
| Q3 2025 | +1.1% | +7.6% | +23.6% | |
| Q2 2025 | +0.1% | -6.0% | +5.8% | |
| Q1 2025 | -2.6% | -1.9% | +11.5% | |
| Q4 2024 | -8.1% | -14.4% | +6.8% | |
| Q3 2024 | -13.5% | -14.8% | -14.5% | |
| Q2 2024 | -6.2% | +3.0% | -10.9% | |
| Q1 2024 | +4.6% | -0.5% | -11.0% | |
| Q4 2023 | +23.3% | +18.6% | -9.1% | |
| Q3 2023 | +11.3% | +18.7% | +37.4% | |
| Q2 2023 | -1.0% | -1.2% | -8.7% | |
| Q1 2023 | +2.2% | +4.7% | +9.5% | |
| Q4 2022 | -5.0% | +3.7% | -3.2% | |
| Q3 2022 | +3.0% | -0.5% | -6.7% | |
| Q2 2022 | -1.0% | -4.3% | -14.2% | |
| Q1 2022 | +2.8% | +6.5% | +57.6% | |
| Q4 2021 | -2.8% | +0.0% | -16.8% | |
| Q3 2021 | -5.9% | -7.7% | -26.6% | |
| Q2 2021 | -1.3% | +2.3% | +5.1% | |
| Q1 2021 | -4.5% | -0.8% | -0.8% | |
| Q4 2020 | +1.1% | +7.4% | -3.9% | |
| Q3 2020 | +0.5% | +64.0% | +93.3% | |
| Q2 2020 | -0.2% | -6.9% | -11.3% | |
| Q1 2020 | -2.4% | -13.8% | +90.3% | |
| Q4 2019 | -4.8% | -3.7% | -23.5% | |
| Q3 2019 | +1.4% | +1.0% | -23.1% | |
| Q2 2019 | +0.7% | -0.4% | -14.9% | |
| Q1 2019 | -2.5% | +0.2% | -6.8% | |
| Q4 2018 | -4.7% | -8.5% | -12.8% | |
| Q3 2018 | -7.2% | -6.2% | -17.8% | |
| Q2 2018 | -1.1% | +2.8% | -15.0% | |
| Q1 2018 | -4.0% | -2.4% | -2.2% | |
| Q4 2017 | -2.4% | -9.9% | +18.6% | |
| Q3 2017 | -5.6% | -15.7% | -13.2% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro